Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Nektar TherapeuticsNASDAQ: NKTR

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin holds steady near 100.0%

Gross margin was 100.0% in Q2 FY2026, up 0.0 pp from a year earlier. On a trailing-twelve-month basis it was 99.4%, up 15.9 pp year over year. Over 3 fiscal years it widened by 23.5 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
100.0%+1.4 pp QoQ
Last fiscal yearDec 2025
100.0%+31.2 pp YoY
LTMJun 2026
99.4%+15.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.0 pp——
1 year+31.2 pp——
3 years+23.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+31.2pp

Gross Margin vs competitors

How NKTR compares with its peers on the latest reported figures

  • NKTR's LTM Jun 2026 gross margin of 99.4% is the 4th highest of the 10 companies compared; the peer median is 94.0%.
  • Its year-over-year change of +15.9 pp is the 2nd highest of 9, against a peer median of +0.0 pp.
  • Over three fiscal years its change of +23.5 pp compares with a peer median of +0.9 pp.
NKTR Competitors Peer median
Gross Margin for NKTR and competitors
Company Period LTM level YoY 3-year change
IMTXImmatics N.V.LTM Mar 2026100.0% +0.1 pp+61.8 pp
ANLAdlai Nortye Ltd.LTM Jun 2024100.0% ——
IPHAInnate Pharma S.A.FY2025100.0% +0.0 pp+89.6 pp
NKTRNektar TherapeuticsLTM Jun 202699.4% +15.9 pp+23.5 pp
IMCRImmunocore Holdings plcLTM Mar 202698.8% -0.2 pp+1.6 pp
RCUSArcus Biosciences, Inc.LTM Jun 202694.0% -6.0 pp-4.0 pp
CGENCompugen Ltd.LTM Mar 202688.1% +17.9 pp+0.3 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
CHRSCoherus Oncology, Inc.LTM Mar 202660.0% +4.5 pp-8.9 pp
XNCRXencor, Inc.LTM Jun 202643.3% -18.0 pp+112.9 pp
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding NKTR) 94.0%+0.0 pp+0.9 pp

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue101.91M92.06M90.12M98.43M55.23M
Cost of Revenue24.9M21.64M36.64M30.69M0
Gross Profit77.01M70.42M53.48M67.74M55.23M
Gross Margin75.6%76.5%59.3%68.8%100.0%
Research & Development400.27M218.32M114.16M120.91M117.33M
Selling, General & Admin122.84M92.33M77.42M76.75M68.67M
Operating Expenses523.11M310.66M190.9M172.94M186M
Depreciation & Amortization14.15M12.2M7.82M4.39M1.03M
EBITDA(461.82M)(323.87M)(243.11M)(86.7M)(137M)
EBITDA Margin-453.2%-351.8%-269.8%-88.1%-248.1%
Operating Income(446.1M)(240.24M)(137.43M)(105.2M)(130.77M)
Operating Margin-437.8%-261.0%-152.5%-106.9%-236.8%
Interest Income2.73M6.78M19.01M14.5M10.44M
Interest Expense47.31M28.91M25.33M28.11M26.18M
Other Income / Expenses(77.18M)(124.75M)(138.83M)(14M)(33.44M)
Income Before Tax(523.28M)(364.98M)(276.26M)(119.2M)(164.21M)
Pre-Tax Margin-513.5%-396.5%-306.5%-121.1%-297.3%
Income Tax Expense557K3.22M(200K)(239K)(138K)
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Net Margin-514.0%-400.0%-306.3%-120.9%-297.1%
EPS (Basic)(42.90)(29.51)(21.79)(8.68)(9.73)
EPS (Diluted)(42.90)(29.51)(21.79)(8.68)(9.73)
Weighted Avg Shares12.22M12.48M12.67M13.71M16.87M
Weighted Avg Shares (Diluted)12.22M12.48M12.67M13.71M16.87M

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.